Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

current versions

No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Doxorubicin‐based maintenance chemotherapy vs observation 3‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1 [0.86, 1.15]	2 studies · 204 participants	Moderate
Doxorubicin‐based maintenance chemotherapy vs observation 5‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1 [0.79, 1.27]	2 studies · 204 participants	Moderate
Maintenance chemotherapy vs maintenance radiotherapy 3‐year PFS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.07 [0.75, 1.54]	1 study · 141 participants	Low
Maintenance chemotherapy vs maintenance radiotherapy 5‐year PFS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.86 [0.55, 1.37]	1 study · 141 participants	Low
Maintenance chemotherapy vs maintenance radiotherapy 10‐year PFS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.89 [0.51, 1.55]	1 study · 141 participants	Low
Maintenance chemotherapy vs maintenance radiotherapy 3‐year OS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.06 [0.85, 1.32]	1 study · 141 participants	Low
Maintenance chemotherapy vs maintenance radiotherapy 5‐year OS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.97 [0.7, 1.35]	1 study · 141 participants	Low
Maintenance chemotherapy vs observation 5‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.06 [0.97, 1.17]	3 studies · 761 participants	Moderate
Maintenance chemotherapy vs maintenance radiotherapy 10‐year OS · epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.94 [0.58, 1.52]	1 study · 141 participants	Low
Maintenance chemotherapy vs observation 10‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.96 [0.65, 1.41]	2 studies · 219 participants	Moderate
Maintenance chemotherapy vs observation 3‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1 [0.92, 1.08]	5 studies · 679 participants	Moderate
Maintenance chemotherapy vs observation 5‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.03 [0.96, 1.1]	4 studies · 899 participants	Moderate
Maintenance chemotherapy vs observation 10‐year OS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.08 [0.78, 1.49]	2 studies · 219 participants	Moderate
Platin‐based maintenance chemotherapy vs observation 3‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.04 [0.86, 1.24]	3 studies · 341 participants	Moderate
Platin‐based maintenance chemotherapy vs observation 5‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 1.18 [0.88, 1.58]	2 studies · 219 participants	Moderate
Platin‐based maintenance chemotherapy vs observation 10‐year PFS · patients with epithelial ovarian cancer Maintenance chemotherapy for ovarian cancer (2013) · Cochrane	RR 0.96 [0.65, 1.41]	2 studies · 219 participants	Moderate
Interferon + chemotherapy vs chemotherapy alone Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	HR 1.14	2 studies · 244 participants	Low
Interferon vs observation alone Adverse event (nausea/ vomiting) · women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 1.21 [0.91, 1.62]	1 study · 293 participants	Low
Interferon + chemotherapy vs chemotherapy alone Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	HR 1.43 [1.02, 2]	2 studies · 244 participants	Low
Interferon + chemotherapy vs chemotherapy alone Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 6.49 [0.41, 102.25]	2 studies · 230 participants	Low
Interferon + chemotherapy vs chemotherapy alone Adverse event (fatigue) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 1.17 [0.82, 1.68]	1 study · 97 participants	Low
Interferon + chemotherapy vs chemotherapy alone Adverse event (neurotoxicity) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 0.87 [0.57, 1.33]	2 studies · 230 participants	Low
Interferon vs observation alone Overall survival · women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	HR 1.14 [0.84, 1.55]	2 studies · 370 participants	Low
Interferon vs observation alone Progression‐free survival · women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	HR 0.99 [0.79, 1.24]	2 studies · 370 participants	Low
Interferon vs observation alone Adverse event (flu‐like symptoms) · women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 2.25 [1.73, 2.91]	1 study · 293 participants	Low
Interferon vs observation alone Adverse event (fatigue) · women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer (2013) · Cochrane	RR 1.54 [1.27, 1.88]	1 study · 293 participants	Low
Dietary modification vs no nutritional intervention Diarrhoea at end of treatment · adults with pelvic cancer undergoing radiotherapy Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic… (2013) · Cochrane	RR 0.66 [0.51, 0.87]	4 studies · 413 participants	Moderate
Dietary modification vs no nutritional intervention Change in weight (kg) comparing end of treatment with baseline · adults with pelvic cancer undergoing radiotherapy Nutritional interventions for reducing gastrointestinal toxicity in adults undergoing radical pelvic… (2013) · Cochrane	no estimate extracted	2 studies · 235 participants	Moderate
Intervention NR PFS¹ · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	HR 1.01 [0.85, 1.19]	1 study · 820 participants	High
Intervention NR OS² · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	HR 0.94 [0.78, 1.13]	1 study · 820 participants	High
Intervention NR Anaemia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	RR 2.74 [1.54, 4.88]	1 study · 803 participants	High
Intervention NR Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	RR 8.09 [3.93, 16.67]	1 study · 803 participants	High
Intervention NR Alopecia (grade 2) · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	RR 0.09 [0.06, 0.14]	1 study · 803 participants	High
Intervention NR Neuropathy (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV) Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer (2013) · Cochrane	RR 0.09 [0.01, 0.66]	1 study · 803 participants	High
Summary of findings: EBRT vs no EBRT Death from all causes · women with stage I endometrial cancer Adjuvant radiotherapy for stage I endometrial cancer (2012) · Cochrane	HR 0.99 [0.82, 1.2]	2628 participants	Moderate
Summary of findings: EBRT vs no EBRT Endometrial carcinoma‐related death · women with stage I endometrial cancer Adjuvant radiotherapy for stage I endometrial cancer (2012) · Cochrane	HR 0.96 [0.72, 1.28]	2965 participants	Moderate
Summary of findings: EBRT vs no EBRT Locoregional recurrence · women with stage I endometrial cancer Adjuvant radiotherapy for stage I endometrial cancer (2012) · Cochrane	HR 0.36 [0.25, 0.52]	2965 participants	High
Summary of findings: EBRT vs no EBRT Severe acute toxicity · women with stage I endometrial cancer Adjuvant radiotherapy for stage I endometrial cancer (2012) · Cochrane	RR 4.68 [1.35, 16.16]	1328 participants	High
Summary of findings: EBRT vs no EBRT Severe late toxicity · women with stage I endometrial cancer Adjuvant radiotherapy for stage I endometrial cancer (2012) · Cochrane	RR 2.58 [1.61, 4.11]	3501 participants	High
Summary of findings: antibiotics vs placebo or no intervention All cause mortality · patients with afebrile neutropenia induced by chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 0.66	46 studies · 5635 participants	High
Summary of findings: antibiotics vs placebo or no intervention Febrile patients and episodes · patients with afebrile neutropenia induced by chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 0.8	54 studies · 6658 participants	Moderate
Summary of findings: antibiotics vs placebo or no intervention Bacteraemia · patients with afebrile neutropenia induced by chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 0.5	53 studies · 6390 participants	High
Summary of findings: quinolone prophylaxis vs TMP‐SMZ prophylaxis All cause‐mortality · cancer patients with afebrile neutropenia following chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 1.07	10 studies · 917 participants	Moderate
Summary of findings: quinolone prophylaxis vs TMP‐SMZ prophylaxis Febrile patients and episodes · cancer patients with afebrile neutropenia following chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 0.92	10 studies · 931 participants	Moderate
Summary of findings: quinolone prophylaxis vs TMP‐SMZ prophylaxis Bacteraemia · cancer patients with afebrile neutropenia following chemotherapy Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy (2012) · Cochrane	RR 0.89	10 studies · 931 participants	Moderate
Intervention NR Overall quality of life change score ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane	no estimate extracted	11 studies · 826 participants	Low
Intervention NR Overall social functioning change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane	no estimate extracted	5 studies · 386 participants	Very low
Intervention NR Overall social functioning change ‐ 6 months' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane	no estimate extracted	2 studies · 110 participants	Moderate
Intervention NR Overall quality of life change score ‐ 6 months' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane	no estimate extracted	2 studies · 115 participants	Moderate
Intervention NR Overall anxiety change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment Exercise interventions on health‐related quality of life for cancer survivors (2012) · Cochrane	no estimate extracted	4 studies · 455 participants	Low